drugset / Trial / NCT07113925
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
Phase 1
Recruiting
114 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
TQB2101 for Injection is an Antibody-Drug Conjugate (ADC) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2025-12
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2101 | Other / unclassified | 0.4 mg/kg | Intravenous |
| Subject | TQB2101 | Other / unclassified | 1.6 mg/kg | Intravenous |